🕔1/22/2009 6:59:00 PM
Biovitrum (STO:BVT) Stockholm, January 22 2009. Biovitrum AB (publ) (STO: BVT) today announced the initiation of a process aiming to spin out its small molecule UK based R&D subsidiary Cambridge Biotechnology (CBT) and a range of primary care projects. The proposed transaction reflects Biovitrum's previously announced decision to focus its in-house R&D on specialist pharmaceuticals and protein therapeutics. Biovitrum has engaged Nomura Code in this process.
Lesen Sie die komplette Artikel▸